The global fondaparinux market accounted for USD 0.613 billion in 2023 and is expected to reach at USD 1.25 billion by 2034 with a CAGR of 6.75% during the forecast period 2024-2034. Growing elderly population, increase in the occurrence of cancer & cardiovascular diseases, surge in research & development efforts, increased funding by major market players, growing demand for generic medications, increase in the prevalence of deep vein thrombosis & thrombocytosis, heightened need for fast-acting & more effective treatments, and increasing approvals of novel fondaparinux products by regulatory authorities are some of the key factors boosting the market growth.
Increasing approvals of novel fondaparinux products by regulatory authorities is predicted to boost the market growth during the forecast period. Fondaparinux, a synthetic anticoagulant, is employed to prevent blood clot formation by targeting the pentasaccharide sequence, which constitutes the essential antithrombin binding region found in heparin. It is utilized in managing cardiac conditions due to its effectiveness in preventing and treating venous thromboembolism, as well as addressing non-ST elevation acute coronary syndromes. Anticoagulants are becoming more prevalent in both medical and surgical settings. For instance, in July 2022, Anthos Therapeutics, a biotechnology company in the clinical stage, focused on creating groundbreaking treatments for cardiovascular and metabolic conditions, has revealed that its investigational Factor XI inhibitor, abelacimab, has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for managing thrombosis linked to cancer.
By product, generics was the highest revenue-grossing segment in the global fondaparinux market in 2023 owing to the availability of generic medications at a reduced cost, offering comparable bioequivalence to innovator products, rise in approvals for new generic drugs, growing prevalence of cardiovascular diseases, increasing aging population, and surge in incidence of cardiovascular disorders contribute to an elevated risk of thrombosis. Additionally, branded is predicted to grow at the fastest CAGR during the forecast period owing to the high cost of medications, patent expirations, the introduction of affordable alternatives, and increasing approvals by regulatory agencies. For instance, in March 2022, The US Food and Drug Administration (FDA) has given accelerated approval to a novel medication for addressing myelofibrosis, marking the first drug specifically designated for individuals with low platelet counts. Pacritinib (marketed as Vonjo by CTI BioPharma) is intended for adults diagnosed with intermediate- or high-risk primary or secondary myelofibrosis (following polycythemia vera or essential thrombocythemia) with a platelet count under 50 × 109/L.
By type, deep vein thrombosis was the highest revenue-grossing segment in the global fondaparinux market in 2023 owing to the growing research & development efforts by key market players, rising government funding, heightened emphasis on drug development, growing demand for precision medicine, and surge of approvals from regulatory bodies. For instance, in December 2023, Novartis, a prominent company specializing in innovative medicines, has revealed that the U.S. Food and Drug Administration (FDA) has granted approval to Fabhalta (iptacopan), making it the initial oral monotherapy authorized for adults diagnosed with paroxysmal nocturnal hemoglobinuria (PNH). Additionally, pulmonary embolism is predicted to grow at the fastest CAGR during the forecast period owing to the rising incidence of blood clotting disorders, increased adoption of telemedicine & remote monitoring practices, and growing emphasis on the development of anticoagulant medications.
By route of administration, oral was the highest revenue-grossing segment in the global fondaparinux market in 2023 owing to the simplicity of use and the increasing number of clinical trial processes. For instance, in February 2023, Bayer has initiated enrollment of the first patients in the initial trials of its OCEANIC clinical trial program. This program aims to investigate the potential of asundexian (BAY2433334), an oral Factor XIa (FXIa) inhibitor, in individuals with atrial fibrillation (AF) and those who have experienced a non-cardioembolic ischemic stroke or are at high risk of transient ischemic attack (TIA), which presents with symptoms similar to those of a stroke on a temporary basis. Additionally, parenteral is predicted to grow at the fastest CAGR during the forecast period owing to the increasing research & development endeavors and growing demand for precision medicines.
By end-user, hospitals was the highest revenue-grossing segment in the global fondaparinux market in 2023 owing to the growing presence of specialty hospitals, both public & private, offering therapeutic services, and uptick in research and development efforts. For instance, in November 2023, Penumbra, Inc., a worldwide healthcare firm dedicated to pioneering therapies, has unveiled new data from the STRIKE-PE study, assessing the Indigo Aspiration System with Lightning. The findings demonstrate that Penumbra's computer-assisted vacuum thrombectomy (CAVT) method is both safe and efficacious in alleviating right heart strain. Additionally, clinics is predicted to grow at the fastest CAGR during the forecast period owing to the growing geriatric population and increase in the prevalence of cancer and cardiovascular diseases.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising burden of cardiovascular disorders, increase in the approval of products, surge in launch of new treatments, growing prevalence of deep vein thrombosis, and increase in research funding for heart diseases. For instance, in September 2022, The Ontario Ministry of Health has incorporated fondaparinux (marketed as Arixtra and generic) into the reimbursement criteria of the exceptional access program. This inclusion applies to commonly requested medications for preventing and treating venous thromboembolism. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing trend towards the introduction of affordable generic versions of Fondaparinux, expanding geriatric demographic, rising incidence of thrombosis, and market players are also implementing numerous initiatives. For instance, in February 2022, China's Joint Procurement Office (JPO) issued a notification to gather drug data for the seventh round of volume-based procurement (VBP) of fondaparinux, aiming to enhance the country's collective purchasing of medications.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Increasing approvals of novel fondaparinux products by regulatory authorities is predicted to boost the market growth during the forecast period. Fondaparinux, a synthetic anticoagulant, is employed to prevent blood clot formation by targeting the pentasaccharide sequence, which constitutes the essential antithrombin binding region found in heparin. It is utilized in managing cardiac conditions due to its effectiveness in preventing and treating venous thromboembolism, as well as addressing non-ST elevation acute coronary syndromes. Anticoagulants are becoming more prevalent in both medical and surgical settings. For instance, in July 2022, Anthos Therapeutics, a biotechnology company in the clinical stage, focused on creating groundbreaking treatments for cardiovascular and metabolic conditions, has revealed that its investigational Factor XI inhibitor, abelacimab, has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for managing thrombosis linked to cancer.
By product, generics was the highest revenue-grossing segment in the global fondaparinux market in 2023 owing to the availability of generic medications at a reduced cost, offering comparable bioequivalence to innovator products, rise in approvals for new generic drugs, growing prevalence of cardiovascular diseases, increasing aging population, and surge in incidence of cardiovascular disorders contribute to an elevated risk of thrombosis. Additionally, branded is predicted to grow at the fastest CAGR during the forecast period owing to the high cost of medications, patent expirations, the introduction of affordable alternatives, and increasing approvals by regulatory agencies. For instance, in March 2022, The US Food and Drug Administration (FDA) has given accelerated approval to a novel medication for addressing myelofibrosis, marking the first drug specifically designated for individuals with low platelet counts. Pacritinib (marketed as Vonjo by CTI BioPharma) is intended for adults diagnosed with intermediate- or high-risk primary or secondary myelofibrosis (following polycythemia vera or essential thrombocythemia) with a platelet count under 50 × 109/L.
By type, deep vein thrombosis was the highest revenue-grossing segment in the global fondaparinux market in 2023 owing to the growing research & development efforts by key market players, rising government funding, heightened emphasis on drug development, growing demand for precision medicine, and surge of approvals from regulatory bodies. For instance, in December 2023, Novartis, a prominent company specializing in innovative medicines, has revealed that the U.S. Food and Drug Administration (FDA) has granted approval to Fabhalta (iptacopan), making it the initial oral monotherapy authorized for adults diagnosed with paroxysmal nocturnal hemoglobinuria (PNH). Additionally, pulmonary embolism is predicted to grow at the fastest CAGR during the forecast period owing to the rising incidence of blood clotting disorders, increased adoption of telemedicine & remote monitoring practices, and growing emphasis on the development of anticoagulant medications.
By route of administration, oral was the highest revenue-grossing segment in the global fondaparinux market in 2023 owing to the simplicity of use and the increasing number of clinical trial processes. For instance, in February 2023, Bayer has initiated enrollment of the first patients in the initial trials of its OCEANIC clinical trial program. This program aims to investigate the potential of asundexian (BAY2433334), an oral Factor XIa (FXIa) inhibitor, in individuals with atrial fibrillation (AF) and those who have experienced a non-cardioembolic ischemic stroke or are at high risk of transient ischemic attack (TIA), which presents with symptoms similar to those of a stroke on a temporary basis. Additionally, parenteral is predicted to grow at the fastest CAGR during the forecast period owing to the increasing research & development endeavors and growing demand for precision medicines.
By end-user, hospitals was the highest revenue-grossing segment in the global fondaparinux market in 2023 owing to the growing presence of specialty hospitals, both public & private, offering therapeutic services, and uptick in research and development efforts. For instance, in November 2023, Penumbra, Inc., a worldwide healthcare firm dedicated to pioneering therapies, has unveiled new data from the STRIKE-PE study, assessing the Indigo Aspiration System with Lightning. The findings demonstrate that Penumbra's computer-assisted vacuum thrombectomy (CAVT) method is both safe and efficacious in alleviating right heart strain. Additionally, clinics is predicted to grow at the fastest CAGR during the forecast period owing to the growing geriatric population and increase in the prevalence of cancer and cardiovascular diseases.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising burden of cardiovascular disorders, increase in the approval of products, surge in launch of new treatments, growing prevalence of deep vein thrombosis, and increase in research funding for heart diseases. For instance, in September 2022, The Ontario Ministry of Health has incorporated fondaparinux (marketed as Arixtra and generic) into the reimbursement criteria of the exceptional access program. This inclusion applies to commonly requested medications for preventing and treating venous thromboembolism. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing trend towards the introduction of affordable generic versions of Fondaparinux, expanding geriatric demographic, rising incidence of thrombosis, and market players are also implementing numerous initiatives. For instance, in February 2022, China's Joint Procurement Office (JPO) issued a notification to gather drug data for the seventh round of volume-based procurement (VBP) of fondaparinux, aiming to enhance the country's collective purchasing of medications.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Product, Type, Route Of Administration, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
Segmentation: Fondaparinux Market Report 2023 - 2034
Fondaparinux Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Generics
- Branded
Fondaparinux Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Pulmonary Embolism
- Deep Vein Thrombosis
Fondaparinux Market Analysis & Forecast by Route Of Administration 2023 - 2034 (Revenue USD Bn)
- Parenteral
- Oral
- Others
Fondaparinux Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Diagnostic Centers
- Hospitals
- Clinics
- Ambulatory Surgical Centres
- Home Care Settings
Fondaparinux Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Fondaparinux Market: Product Estimates & Trend Analysis
8. Fondaparinux Market: Type Estimates & Trend Analysis
9. Fondaparinux Market: Route Of Administration Estimates & Trend Analysis
10. Fondaparinux Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Fondaparinux Market
13. Europe Global Fondaparinux Market
14. Asia Pacific Global Fondaparinux Market
15. Latin America Global Fondaparinux Market
16. MEA Global Fondaparinux Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Jiangsu Hengrui Medicine Co. Ltd
- Dr. Reddy's Laboratories Ltd
- Apotex Inc.
- GSK plc
- Scinopharm Taiwan Ltd
- Pfizer Inc.
- GSK plc
- Aurobindo Pharma Ltd
- Eugia
- Boehringer Ingelheim International GmbH
